MedTrace Logo

2-week dc of MTX and Influenza Vaccination in RA

NCT02897011 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 318

Last updated 2016-10-27

No results posted yet for this study

Summary

To investigate whether a transient discontinuation of methotrexate MTX for 2 weeks improves the vaccination response to a seasonal influenza.

Conditions

Interventions

DRUG

Methotrexate

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02897011 on ClinicalTrials.gov